Pediatrix Medical Group, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Amounts below are in U.S. dollars; financial amounts are in millions unless stated otherwise. Pediatrix provides physician services focused on newborn, maternal-fetal, pediatric cardiology and other pediatric specialty care across 37 states.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net revenue | $506.6 | $489.9 | $1,498.2 | $1,458.2 |
| Income from operations | $40.3 | $47.4 | $118.8 | $136.7 |
| Operating margin | 7.9% | 9.7% | 7.9% | 9.4% |
| Income from continuing operations | $21.4 | $28.8 | $63.9 | $38.6 |
| Net income attributable to Pediatrix | $21.4 | $30.7 | $63.9 | $36.7 |
| Diluted EPS | $0.26 | $0.37 | $0.77 | $0.43 |
| Adjusted EBITDA from continuing operations | $50.4 | $58.3 | $149.6 | $174.5 |
| Adjusted EPS from continuing operations | $0.32 | $0.40 | $0.94 | $1.20 |
- Q3 revenue rose 3.4%; same-unit revenue increased 4.1%, reflecting a 5.3% increase from reimbursement-related factors, partly offset by a 1.2% decline in patient-service volume. Nine-month revenue rose 2.7%, with same-unit revenue up 2.8%.
- Q3 practice salaries and benefits increased 7.4% to $368.4 million, outpacing revenue growth. Management attributed this to clinical compensation, incentive compensation, malpractice expense and health insurance costs. General and administrative expense decreased to $57.4 million; as a share of revenue, it fell to 11.3% from 11.8%.
- Lower operating income and adjusted EBITDA primarily reflected higher same-unit operating costs. Nine-month GAAP earnings benefited in comparison with 2022, which included a $57.0 million debt-extinguishment loss; adjusted EBITDA and adjusted EPS declined year over year.
- Interest expense was $10.4 million in Q3 and $32.0 million for nine months. The nine-month 2023 tax rate was 29.4%, including $2.0 million of discrete tax expense; management reported a 27.2% rate excluding discrete items.
Cash flow, liquidity and debt
- Nine-month cash provided by continuing operations was $73.1 million, compared with $80.0 million in 2022. Capital expenditures were $24.3 million. Cash and cash equivalents were $21.2 million at September 30, 2023.
- Current assets were $420.5 million and current liabilities were $350.4 million, resulting in working capital of $70.1 million. Short-term investments were $103.5 million; cash plus short-term investments totaled $124.7 million.
- Debt principal comprised $231.3 million outstanding under the Term A Loan and $400.0 million of 5.375% senior notes due 2030. No revolving-credit borrowings were outstanding; the company reported $450.0 million available under its credit agreement. The Term A Loan and revolving facility mature in February 2027.
- The company reported compliance with debt covenants and expected to remain compliant through 2023. Management expects operating cash flow, cash on hand and available credit to fund working capital and anticipated needs for at least 12 months from the filing date. A 1% interest-rate change on the Term A Loan balance would affect annual pretax income by approximately $2.3 million.
- Days sales outstanding improved to 50.4 days from 53.1 at year-end 2022 and 55.3 a year earlier, which management attributed primarily to better collections.
Outlook, risks and notable developments
- No formal numerical revenue or earnings guidance is provided in the filing. Management expects clinician compensation costs to continue growing faster than historical averages, which could pressure results.
- On October 30, 2023, Pediatrix gave notice terminating R1 RCM’s revenue-cycle-management services agreement, effective December 15, 2023, following service-level performance issues. The company plans to move to a hybrid model using internal staff and third-party providers. It warned that transition or integration problems could delay collections, increase denials or otherwise harm revenue, cash flow and operations. Early termination fees were expected to be immaterial; R1 is to provide transition assistance.
- Reimbursement is exposed to payor mix, government-program rates, patient ability to pay and the evolving No Surprises Act and independent dispute-resolution process. Management noted pending litigation and rulemaking could affect reimbursement and dispute outcomes.
- Professional liability is a material exposure: reported liabilities were $295.7 million, including $30.2 million current, with a related $40.6 million insurance receivable for certain covered claims. Pediatrix self-insures a portion of professional liability risk; coverage may not be sufficient for all claims. Government audits, inquiries, malpractice claims and other litigation are additional contingencies whose outcomes are uncertain.
- COVID-19 had no material operating impact since the recovery in 2020, according to the company, but future effects remain uncertain. Disclosure controls were assessed as effective as of September 30, 2023.
Key facts for investors to verify
- Execution of the R1 contract termination and revenue-cycle transition, including collections, denials, costs and service continuity.
- Whether clinician compensation and other practice costs continue to outpace revenue growth and further pressure operating margins.
- Revenue quality: reimbursement and collection trends, patient volumes, payor mix and DSO performance.
- Debt covenant headroom, variable-rate exposure and liquidity available after operating and investment needs.
- Developments in professional liability claims, insurance recoveries, government inquiries and No Surprises Act disputes.